Skip to main content

Table 4 Mortality and overall survival in 181 node-negative breast cancer patients after different adjuvant systemic therapies or no therapy

From: C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer

Subgroup   n Mortality (n [%]) OS (P)
Chemotherapy (n = 61)
   c-myc Amplified 19 1 (5.3) 0.7442
  Nonamplified 42 3 (7.1)  
HER-2/neu Amplified 26 0 (0.0) 0.1042
  Nonamplified 35 4 (11.4)  
Endocrine therapy (n= 99)
   c-myc Amplified 15 1 (6.7) 0.9846
  Nonamplified 84 6 (7.1)  
HER-2/neu Amplified 22 2 (9.1) 0.8307
  Nonamplified 77 5 (6.5)  
No therapy (n = 21)
   c-myc Amplified 5 2 (40.0) 0.0098*
  Nonamplified 16 1 (6.3)  
HER-2/neu Amplified 7 1 (14.3) 0.5649
  Nonamplified 14 2 (14.3)  
  1. *P < 0.05 (log-rank test). OS, overall survival.